These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 111465)

  • 1. Suppression of uterine activity by prostaglandin synthetase inhibitors.
    Pulkkinen MO
    Acta Obstet Gynecol Scand Suppl; 1979; 87():39-43. PubMed ID: 111465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rationale for the treatment of dysmenorrhea.
    Csapo AI
    J Reprod Med; 1980 Oct; 25(4 Suppl):213-21. PubMed ID: 7001020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous prostaglandins in dysmenorrhea and the effect of prostaglandin synthetase inhibitors (PGSI) on uterine contractility.
    Lundström V; Gréen K; Svanborg K
    Acta Obstet Gynecol Scand Suppl; 1979; 87():51-6. PubMed ID: 111466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of ibuprofen and naproxen sodium on menstrual prostaglandin release and on prostaglandin production in the rat uterine homogenate.
    Powell AM; Chan WY
    Prostaglandins Leukot Med; 1984 Feb; 13(2):129-37. PubMed ID: 6585839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of naproxen-sodium on the intrauterine pressure and menstrual pain of dysmenorrheic patients.
    Csapo AI; Pulkkinen MO; Henzl MR
    Prostaglandins; 1977 Jan; 13(1):193-9. PubMed ID: 320630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of naproxen-sodium on the prostaglandin concentrations of the menstrual blood and uterine "jet-washings" in dysmenorrheic women.
    Pulkkinen MO; Henzl MR; Csapo AI
    Prostaglandins; 1978 Mar; 15(3):543-50. PubMed ID: 351717
    [No Abstract]   [Full Text] [Related]  

  • 7. Naproxen and naproxen sodium in dysmenorrhea: development from in vitro inhibition of prostaglandin synthesis to suppression of uterine contractions in women and demonstration of clinical efficacy.
    Henzl MR; Izu A
    Acta Obstet Gynecol Scand Suppl; 1979; 87():105-17. PubMed ID: 380249
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of inhibitors of prostaglandin synthesis in primary dysmenorrhea studied with hysterometry.
    Joelsson I; Lalos O
    Acta Obstet Gynecol Scand Suppl; 1979; 87():45-49. PubMed ID: 380251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terbutaline inhibition of midtrimester uterine activity induced by prostaglandin F2alpha and hypertonic saline.
    Andersson KE; Bengtsson LP; Ingemarsson I
    Br J Obstet Gynaecol; 1975 Sep; 82(9):745-9. PubMed ID: 1182093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effect of high-intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patients with primary dysmenorrhea.
    Milsom I; Hedner N; Mannheimer C
    Am J Obstet Gynecol; 1994 Jan; 170(1 Pt 1):123-9. PubMed ID: 8296814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary dysmenorrhea with prostaglandin synthetase inhibitors--a promising therapeutic alternative.
    Lundström V
    Acta Obstet Gynecol Scand; 1978; 57(5):421-8. PubMed ID: 103358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations.
    Dawood MY
    Drugs; 1981 Jul; 22(1):42-56. PubMed ID: 6790261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin F2 alpha and E2 in primary dysmenorrhea.
    Lundström V; Bygdeman M
    Adv Prostaglandin Thromboxane Res; 1980; 8():1455-8. PubMed ID: 6769314
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of primary dysmenorrhea with prostaglandin synthetase inhibitors].
    Lundström V
    Lakartidningen; 1979 Feb; 76(8):614-6. PubMed ID: 105214
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostaglandin F2 alpha, oxytocin, and uterine activation in hypertonic saline-induced abortions.
    Fuchs AR; Rasmussen AB; Rehnström J; Toth M
    Am J Obstet Gynecol; 1984 Sep; 150(1):27-32. PubMed ID: 6476024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of the etiology and management of dysmenorrhea in adolescence.
    Alvin PE; Litt IF
    Pediatrics; 1982 Oct; 70(4):516-25. PubMed ID: 6812011
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of uterine activity and abortion by inhibition of prostaglandin synthesis.
    Csapo AI; Henzl MR; Kaihola HL; Kivikoski A; Pulkkinen MO
    Prostaglandins; 1974 Jul; 7(1):39-47. PubMed ID: 4605187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of uterine motor activity by prostaglandin synthetase inhibitor Naproxen.
    Herczeg J; Falkay G; Sas M
    Acta Biol Med Ger; 1978; 37(5-6):953-4. PubMed ID: 105529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrauterine pressure changes during dysmenorrhea therapy.
    Smith RP; Powell JR
    Am J Obstet Gynecol; 1982 Jun; 143(3):286-92. PubMed ID: 6805330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of flurbiprofen and naproxen sodium on intra-uterine pressure and menstrual pain in patients with primary dysmenorrhea.
    Milsom I; Andersch B; Sundell G
    Acta Obstet Gynecol Scand; 1988; 67(8):711-6. PubMed ID: 3074603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.